Join the Heart Attack group to help and get support from people like you.
Heart Attack News (Page 3)
AHA: GLP-1 RA, SGLT-2i Use Can Lower Risk for MI, Recurrent Stroke in Stroke Survivors
TUESDAY, Nov. 12, 2024 – For patients with ischemic stroke, sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with reduced...
When Is It OK to Undergo Routine Surgery After a Heart Attack?
FRIDAY, Nov. 1, 2024 – Seniors who’ve had a heart attack should probably delay any elective surgeries for three to six months, a new study advises. People aged 67 and older face double to triple the ...
Could Constipation Be a Risk to the Heart?
WEDNESDAY, Oct. 30, 2024 – Constipation might increase a person’s risk of having a heart attack or stroke, particularly if they also have high blood pressure, a new study warns. People who are c...
Study Looks at Efficacy of Hemoglobin Thresholds for Transfusion
TUESDAY, Oct. 1, 2024 – For patients with acute myocardial infarction (MI) and anemia, 30-day risks for death or recurrent MI seem to increase with lower hemoglobin thresholds for transfusion,...
Acute Myocardial Infarction Up in People With Epilepsy, 2008 to 2017
WEDNESDAY, Sept. 18, 2024 – The prevalence of acute myocardial infarction (AMI) in people with epilepsy increased from 2008 to 2017, according to a study published online Aug. 4 in Frontiers in...
Feeling Content Helps Shield You From Heart Attack, Stroke
WEDNESDAY, Sept. 18, 2024 – Folks who are content with what they’ve got could be less likely to suffer a heart attack or stroke, a new study suggests. “Our findings support a holistic approach to hea...
FDA Approves Praluent (alirocumab) to Prevent Heart Attack, Stroke and Unstable Angina Requiring Hospitalization
PARIS and TARRYTOWN, NY – April 26, 2019 – The U.S. Food and Drug Administration (FDA) has approved Praluent (alirocumab) to reduce the risk of heart attack, stroke, and unstable angina requiring hos...
Victoza (liraglutide) is Approved to Reduce the Risk of Three Major Adverse Cardiovascular Events in Type 2 Diabetes Patients
PLAINSBORO, N.J., Aug. 25, 2017 /PRNewswire/ – The U.S. Food and Drug Administration (FDA) has approved a new indication for Victoza (liraglutide) to reduce the risk of major adverse cardiovascular...
FDA Approves Expanded Indication for Brilinta to Include Long-Term Use in Patients with a History of Heart Attack
Thursday, 3 September 2015 – AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Brilinta (ticagrelor) tablets at a new 60mg dose to be used in patients with a...
FDA Approves Zontivity to Reduce the Risk of Heart Attacks and Stroke
May 8, 2014 – The U.S. Food and Drug Administration today approved Zontivity (vorapaxar) tablets to reduce the risk of heart attack, stroke, cardiovascular death, and need for procedures to restore...
FDA Medwatch Alert: Nitroglycerin in 5% Dextrose Injection by Baxter: Recall - Particulate Matter
ISSUE: Baxter International Inc has initiated a voluntary recall of one lot of Nitroglycerin in 5% Dextrose Injection due to particulate matter found in one vial. If infused, particulate matter could...
Further information
Related drug support groups
lisinopril, metoprolol, aspirin, propranolol, warfarin, Plavix, atenolol, Coumadin, Metoprolol Succinate ER, view more... clopidogrel, Metoprolol Tartrate, Brilinta, valsartan, ramipril, Lovenox, Arthritis Pain, nitroglycerin, Diovan, ticagrelor